טוען...
The Src Family Kinase/Abl Inhibitor Dasatinib Suppresses Proliferation and Enhances Differentiation of Osteoblasts
Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate cancer in bone, but the effect of dasatinib on...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2921959/ https://ncbi.nlm.nih.gov/pubmed/20228840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2010.73 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|